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Abstract Inhibitors of the vascular endothelial growth factor
(VEGF) pathway frequently induce hypertension when used
to treat patients with advanced renal cell carcinoma (RCC).
This analysis characterizes hypertension and hypertension-
related events in patients treated with the VEGF pathway
inhibitors axitinib or sorafenib in the AXIS trial. AXIS was
a randomized phase III study of axitinib versus sorafenib in
patients with metastatic RCC following failure of one prior
systemic regimen. Patients with uncontrolled hypertension
were excluded, but patients with hypertension controlled with
antihypertensive medication were allowed to participate.
Guidelines for hypertensionmanagement included adjustment
or addition of antihypertensive medications and/or axitinib or
sorafenib dose reductions, interruptions, or discontinuations.
Treatment-emergent all-causality hypertension occurred in
145 (40.4 %) axitinib-treated patients (N=359) and 103
(29.0 %) sorafenib-treated patients (N=355), with grade 3
hypertension reported in 55 (15.3 %) and 38 (10.7 %) patients,
respectively, and grade 4 hypertension reported in one (0.3 %)
patient in each arm. Hypertension-related events led to axitin-
ib dose interruptions (n=46; 12.8 %), dose reductions (n=16;
4.5 %), or discontinuations (n=1; 0.3 %). Approximately 50 %
of axitinib-treated patients with grade 3 or 4 hypertension con-
tinued treatment for ≥ 9 months. Hypertension-related sequelae
occurred in <1 % of axitinib-treated patients. Hypertension was
more frequently observed during treatment with axitinib than
sorafenib in patients with RCC, but axitinib-induced hyperten-
sion rarely led to treatment discontinuation or cardiovascular
sequelae. Recommendations for monitoring blood pressure and
managing hypertension during axitinib therapy are presented.
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Introduction
Axitinib is a tyrosine kinase inhibitor of vascular endothelial
growth factor (VEGF) receptors 1–3 [1]. The phase III AXIS
trial was conducted to compare progression-free survival
(PFS) in patients with metastatic renal cell carcinoma (RCC)
treated with axitinib versus sorafenib, an active comparator,
following failure of one prior systemic regimen [2]. Median
PFS was 6.7 months with axitinib versus 4.7 months with
sorafenib (hazard ratio = 0.665; one-sided p<0.0001).
Occurrence of hypertension with use of VEGF pathway
inhibitors has been well documented [3–7]. All-grade hyper-
tension, ranging from 17 to 40 %, has been reported in studies
of axitinib, bevacizumab/interferon-alpha, sunitinib, sorafenib,
and pazopanib in patients with RCC [2, 8–11]. Although the
B. I. Rini (*) : L. S. Wood
Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic Main
Campus, Mail Code R35, 9500 Euclid Avenue,
Cleveland 44195, OH, USA
e-mail: rinib2@ccf.org
D. I. Quinn
University of Southern California Norris Comprehensive Cancer
Center, Los Angeles, CA, USA
M. Baum : R. J. Motzer
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J. Tarazi : B. Rosbrook : S. Kim
Pfizer Oncology, San Diego, CA, USA
L. S. Arruda
Pfizer Inc, Collegeville, PA, USA
L. Cisar
Pfizer Oncology, New York, NY, USA
W. G. Roberts
Pfizer Safety Strategy Risk Management, Groton, CT, USA
Targ Oncol (2015) 10:45–53
DOI 10.1007/s11523-014-0307-z
exact mechanism by which VEGF pathway inhibitors induce
hypertension has not been determined definitively, two key
hypotheses have been generated. Firstly, acute inhibition of
VEGF signaling can lead to disruption of vasodilator production
and subsequent arteriolar vasoconstriction. Studies have pointed
to a VEGF pathway inhibitor-induced decrease in nitric oxide
synthase and nitric oxide production that can result in vasocon-
striction and increased blood pressure (BP) [1, 12–14]. Secondly,
a decrease in the number of microvascular endothelial cells and
subsequent depletion of normalmicrovessel density (rarefaction)
occurs upon VEGF signaling inhibition [14–17].
Hypertension associated with VEGF pathway inhibitors is
often observed in the context of preexisting hypertension. The
Centers for Disease Control and Prevention reported the inci-
dence of hypertension from 2005 to 2008 in the US general
population, ages 45–64 years, was 40.6 % (95 % confidence
interval [CI], 38.1–43.2) [18]. For those aged ≥65 years, the
incidence was 70.3 % (95 % CI, 67.5–73.2). Furthermore, an
epidemiologic study of 1,136 patients with RCC reported
hypertension as a comorbid condition in 58 % of patients at
the time of diagnosis [19].
In the AXIS study, hypertension was the second-most
common adverse event (AE) in the axitinib arm, occurring
in 40 % of patients, and was more frequently reported in
axitinib-treated versus sorafenib-treated patients (29 %) [2].
Herein, hypertension and its management strategies in the
AXIS trial are described, with a focus on axitinib treatment.
Patients and methods
Patients
As described elsewhere [2], eligible patients had histologically or
cytologically confirmed RCC with clear-cell component, mea-
surable disease per Response EvaluationCriteria in Solid Tumors
(RECIST) 1.0 [20], and RECIST-defined progressive disease, as
assessed by investigators, after one prior sunitinib-, bevacizumab/
interferon-alpha-, temsirolimus-, or cytokine-based regimen.
Patients were required to have no evidence of preexisting
uncontrolled hypertension (BP >140/90 mmHg) as determined
by two baseline BP readings taken ≥1 h apart. Patients with BP
controlled by antihypertensive therapy were eligible.
The trial was approved by the institutional review board or
ethics committee at each center and complied with Good
Clinical Practice guidelines, the Declaration of Helsinki, and
local laws. All patients provided written informed consent.
AXIS is registered on ClinicalTrials.gov (NCT00678392).
Procedures
Details of study design and statistical methods have been
reported [2]. Patients were stratified according to Eastern
Cooperative Oncology Group performance status (ECOG
PS) and type of prior treatment and then randomized 1:1 to
axitinib or sorafenib. The primary endpoint was PFS based on
independent radiology review committee assessment.
Axitinib was administered orally at a starting dose of 5 mg
twice daily. Sorafenib was administered orally at a starting
dose of 400 mg twice daily. Dose modifications of axitinib
and sorafenib were previously described [2, 21]. Patients were
treated until disease progression, occurrence of unacceptable
toxicity, death, or withdrawal of consent.
Assessment of medical history, physical examination, vital
signs, clinical laboratory evaluation, and ECOG PS were
performed at baseline, week 2, week 4, and every 4 weeks
thereafter [2]. Safety was assessed throughout the study.
Severity of AEs was graded according to Common
Terminology Criteria for Adverse Events (CTCAE) 3.0 [22].
Management of hypertension
Patients were issued oscillometric BP cuffs and instructed to
measure BP at home twice daily prior to taking study drug. All
measurements were to be taken in a seated position after
resting for 5 min and recorded in a diary. Patients were
instructed to contact their physicians immediately if systolic
BPwas >150mmHg, diastolic BPwas >100mmHg, or if they
developed symptoms perceived to be related to elevated BP
(e.g., headache, visual disturbance).
Hypertension management guidelines for patients receiv-
ing axitinib (Table 1) were based on two BP readings, prefer-
ably taken in-clinic and separated by ≥1 h. Patients receiving
antihypertensive medications who had axitinib withheld were
instructed to monitor closely for hypotension. Due to the short
plasma half-life of axitinib (2.5–6.1 h) [23], BP was expected
to decrease within 1–2 days following dose interruption.
In patients receiving sorafenib, temporary or permanent
discontinuation of drug was to be considered in cases of
severe or persistent hypertension despite administration of
antihypertensive medications.
Statistical analysis
Analyses were conducted in the safety population (patients
who received at least one dose of study drug).
Results
Patients
Of 723 enrolled patients, 361 were randomized to axitinib and
362 to sorafenib; 359 and 355 patients, respectively, were
included in the safety population. Baseline characteristics
were similar between treatment arms [2]. In axitinib and
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sorafenib arms, respectively, 164 (45.4 %) and 189 (52.2 %)
patients had a medical history of hypertension and 167
(46.5 %) and 171 (48.2 %) were receiving antihypertensive
medication prior to the start of study treatment (Table 2).
Incidence of hypertension
Treatment-emergent, all-causality hypertension was reported
in 145 (40.4 %) patients receiving axitinib and 103 (29.0 %)
patients receiving sorafenib (Table 3), of which 141 (97.2 %)
and 103 (100 %) patients, respectively, had treatment-related
hypertension per the investigator. Grade 3 hypertension was
reported in 55 (15.3 %) patients receiving axitinib and 38
(10.7 %) patients receiving sorafenib. One (0.3 %) patient in
each arm experienced grade 4 hypertension. No fatal (grade 5)
hypertension events were reported.
Hypertensive crisis (defined as a potentially life-threatening
increase in BP) was reported in none of the sorafenib-treated
patients and in two (0.6 %) axitinib-treated patients. The first
patient had a prior history of thrombosis and baseline BP of
120/80 mmHg. After 2 weeks of treatment with axitinib 5 mg
twice daily, this patient’s highest home BP reading was 142/
91 mmHg, and clonidine was given for 2 weeks and then
discontinued. A few days later, a home BP reading reached a
maximum of 193/122 mmHg. Axitinib was withheld tempo-
rarily, and treatment with irbesartan/hydrochlorothiazide (150/
12.5 mg) was initiated. The patient subsequently restarted
axitinib and had ongoing grade 1 hypertension. The patient
continued axitinib at 5 mg twice daily and completed
5.8 months of axitinib treatment as of the data cutoff date.
The second axitinib-treated patient had a history of coro-
nary artery disease and was treated with axitinib 5 mg twice
Table 1 Guidance on axitinib dose interruption and reduction for hypertension in the AXIS trial
Degree of BP elevation
Systolic Diastolic Management
Two readings separated
by ≥1 h showing >150 mmHg
OR Two readings separated by ≥1 h
showing >100 mmHg
If not on maximal antihypertensive treatment,
institute new or additional antihypertensive
medication and maintain axitinib dose. If on
maximal antihypertensive treatment, reduce
to one lower dose level
Two readings separated
by ≥1 h showing >160 mmHg
OR Two readings separated by ≥1 h
showing >105 mmHg
Interrupt dosing; adjust antihypertensive
medication; as soon as BP <150/100 mmHg,
restart axitinib at one lower dose level
Recurrent >150 mmHg
(two readings separated by ≥1 h)
following previous dose reduction
OR Recurrent >100 mmHg
(two readings separated by ≥1 h)
following previous dose reduction
Repeat axitinib dose reduction by one lower
dose level
BP blood pressure
Table 2 Antihypertensive medication use




Before first dose of axitinib
Receiving antihypertensive medication 167 (46.5) 171 (48.2)
Amlodipine or amlodipine besylate (calcium channel blocker) 54 (15.0) 47 (13.2)
Atenolol (β1-receptor antagonist) 20 (5.6) 14 (3.9)
Hydrochlorothiazide (diuretic) 18 (5.0) 16 (4.5)
Lisinopril (ACE inhibitor) 16 (4.5) 25 (7.0)
Ramipril (ACE inhibitor) 22 (6.1) 10 (2.8)
On-study
Started antihypertensive medication or increased dose
of existing antihypertensive medication
196 (54.6) 141 (39.7)
Amlodipine or amlodipine besylate (calcium channel blocker) 88 (24.5) 61 (17.2)
Atenolol (β1-receptor antagonist) 18 (5.0) 8 (2.3)
Hydrochlorothiazide (diuretic) 19 (5.3) 13 (3.7)
Lisinopril (ACE inhibitor) 27 (7.5) 14 (3.9)
ACE angiotensin-converting enzyme
aAdministered to ≥5 % of patients
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daily with an increase to 7 mg twice daily at week 2 of
treatment. At month 4 of treatment, the patient experienced
hypertensive crisis with BP 180/100 mmHg and was treated at
a local hospital. Axitinib was withheld, and the event resolved
within 10 days. Axitinib was restarted at 5 mg twice daily, and
the patient completed 8.3 months of treatment as of the data
cutoff date. No other cardiovascular toxicities were reported
for either patient while on study.
Onset of hypertension
Median time to onset of grades 1–2 hypertension in the
axitinib versus sorafenib arms was 16 versus 13 days, whereas
median time to onset of grade ≥3 hypertension was 24 versus
9 days.
When grouped according to baseline antihypertensive
medication use versus non-use, median time to onset of
grade ≥3 events was 15 versus 29 days, respectively, in
the axitinib arm (Table 4). In sorafenib-treated patients,
median time to onset of grade ≥3 hypertension was
similar in both subgroups.
Hypertension-related medical history, hypertension sequelae,
and clinical management of hypertension in axitinib-treated
patients
Hypertension-related medical history recorded for axitinib-
treated patients included angina pectoris (n=4), cerebrovas-
cular accident (n=2), myocardial infarction (n=6), myocardial
ischemia (n=8), and transient ischemic attack (n=2). Of these
patients, seven reported an AE of hypertension on study but
none experienced additional cardiovascular events.
Rates of individual hypertension-related sequelae were
generally low (<1 %) in axitinib-treated patients (Table 5).
In seven of nine patients who experienced hypertension-
related sequelae, hypertension within the first 8 weeks of
treatment was reported either as an AE or as elevated BP,
based on in-clinic or home monitoring. One of the two re-
maining patients had an increased home BP reading within the
first 8 weeks of treatment from 120/80 to 140/90 mmHg 1 day
after discontinuing amlodipine.
Based on in-home and in-clinic BP monitoring, hyperten-
sion events were managed by treatment with antihypertensive
medication (Table 2) and by axitinib dose interruptions
(12.8 %), dose reductions (4.5 %), and/or discontinuation
(0.3%). Of 56 axitinib-treated patients who experienced grade
≥3 hypertension, 30 (53.6 %) continued axitinib treatment for
≥9 months.
Nineteen (5.3 %) axitinib-treated patients experienced
hypotension while on study; of these, hypertension,
accelerated hypertension, or increased BP was reported
in eight (42.1 %) patients. In the majority of cases,
hypotension was considered to have resulted from axi-
tinib dose modification or interruption and/or adminis-
tration of antihypertensive therapy. A serious AE of
hypotension requiring hospitalization was reported in
one axitinib-treated patient and associated with volume
depletion, nausea, vomiting, acute renal failure, and
prerenal azotemia; the event was considered by the
investigator to be unrelated to axitinib treatment.
Blood pressure trends during axitinib treatment
In patients receiving axitinib, median values for maximum
and last on-treatment in-clinic BP readings were higher than
for baseline readings, but returned to baseline after axitinib
discontinuation. Similar trends were observed using change in
diastolic BP from baseline (Table 6).
Table 3 All-causality hypertension-related adverse events
Preferred terma Axitinib (N=359) n (%) Sorafenib (N=355) n (%)
All grades Grade 3/4b All grades Grade 3/4b
Hypertensionc 145 (40.4) 56 (15.6) 103 (29.0) 39 (11.0)
BP increased 3 (0.8) 1 (0.3) 3 (0.8) 2 (0.6)
Hypertensive crisis 2 (0.6) 2 (0.6) 0 0
Accelerated hypertensiond 1 (0.3) 1 (0.3) 0 0
BP blood pressure, CTCAE Common Terminology Criteria for Adverse Events
aMedical Dictionary for Regulatory Activities (MedDRA), v.13.1
bNo grade 5 all-causality hypertension-related events were reported
c Per CTCAE v3.0 [22]; grade 1 hypertension—asymptomatic, transient (<24 h) increase in BP to >150/100 mmHg or in diastolic BP by >20 mmHg
with intervention not indicated; grade 2 hypertension—recurring or persistent (≥24 h) increase in BP to >150/100 mmHg or in diastolic BP by
>20 mmHg with monotherapy possibly indicated; grade 3 hypertension—requiring more than one drug or more intensive therapy; and grade 4
hypertension—BP increases with life-threatening consequences
d Progressive hypertension with the funduscopic vascular changes of malignant hypertension but without papilledema
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Discussion
Although hypertension was the second-most commonly re-
ported treatment-emergent AE in the axitinib arm and more
frequently reported in patients treated with axitinib versus
sorafenib [2], the incidence of potential hypertension-related
sequelae was low with axitinib. There was a slightly higher
incidence of hypertension, proteinuria, and hypothyroidism in
those patients who did not have their axitinib dose increased
(≤5 mg twice daily throughout the study; data not shown).
These results should be interpreted with caution since patients
were not prospectively randomized to receive an increase in
dose above the twice-daily 5 mg starting dose or not, and dose
increases were specified in the protocol based on individual
patient tolerability. As previously reported, hypertension oc-
curred as early as day 1 of treatment with axitinib [24] or
sorafenib [25]. Median time to onset of all-grade hypertension
was independent of baseline antihypertensive use; however, in
the axitinib arm, time to onset of grade ≥3 hypertension was
nearly twice as long in patients not receiving antihypertensive
medications at baseline. This may reflect closer monitoring of
patients receiving antihypertensive therapy at baseline, ac-
cording to standard of care, leading to a tendency toward an
earlier reporting of grade ≥3 hypertension. Alternatively, pa-
tients already receiving antihypertensive medicationmay have
been more biologically susceptible to earlier axitinib-induced
hypertension.
In the AXIS trial, the severity of hypertension was graded
according to CTCAE 3.0 [22]. The definition of hypertension
in this version does not include patients with BP 140–150/90–
100 mmHg and has overlapping definitions of grade 2 and 3
hypertension, which may be inconsistently applied by clini-
cians in grading hypertension. The most recent version of
CTCAE, version 4.0 [26], was updated subsequent to trial
initiation and includes hypertension grading definitions simi-
lar to recommendations from the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure [27], i.e., inclusion of BP ≥140/90 mmHg in
Table 4 Time to onset of hypertension event according to antihypertensive medication use at baseline
Axitinib (N=359) Sorafenib (N=355)










Any grade, n (%) 87 (45.3) 62 (37.1) 56 (30.4) 50 (29.2)
Median, days (range) 15 (1–371) 15 (1–199) 13 (1–368) 8 (1–367)
Grade ≥3, n (%) 26 (13.5) 33 (19.8) 11 (6.0) 30 (17.5)
Median, days (range) 29 (1–165) 15 (1–199) 9.0 (1–267) 9.5 (3–467)
a Included all-causality, treatment-emergent adverse events reported as accelerated hypertension, blood pressure increase, hypertension, or hypertensive
crisis
Table 5 Incidence of potential hypertension-related sequelae in axitinib-treated patients
Axitinib (N=359)
n (%)
Baseline features of individual patients




TIA 3 (0.8) 3 (0.8) 0 Arterial hypertension 120/80 No
High cholesterol 120/80 No
Diabetes 127/74 Yes
Hypertensive crisis 2 (0.6) 2 (0.6) 0 CHD 130/85 NA
Thrombosis 110/70 No
Angina pectoris 1 (0.3) 0 0 Diabetes 115/75 No
Cerebral hemorrhage 1 (0.3) 1 (0.3) 0 TIA 129/82 No
Cerebrovascular accident 1 (0.3) 0 1 (0.3) None 100/60 Yes
Leukoencephalopathyd 1 (0.3) 1 (0.3) 0 Atrial fibrillation 115/62 No
BP blood pressure, TIA transient ischemic attack, CHD coronary heart disease, NA not available
aMedical Dictionary for Regulatory Activities (MedDRA), v.13.1
b Blood pressure at screening visit
c Antihypertensive medication use on cycle 1 day 1 of axitinib treatment
d Reports of reversible posterior leukoencephalopathy syndrome were reported as leukoencephalopathy
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the definition of grade 2 hypertension. Future application of
standardized, less ambiguous definitions and grading of hy-
pertension will help identify and treat patients who develop
hypertension while receiving VEGF-targeting drugs.
The low incidence of hypertensive crisis and hypertension-
related sequelae, and the 27- and 25-day median duration of
hypertension (data not shown) in the axitinib and sorafenib
arms, respectively, suggest that AXIS trial guidelines for
managing hypertension were effective. However, managing
hypertensionmay bemore challenging among patients receiv-
ing VEGF pathway inhibitors in non-trial settings, wherein
patients are not required to meet strict eligibility criteria for a
clinical study. Management of hypertension in patients with
RCC receiving sorafenib has been reported elsewhere
[28–30]. Based on clinical experience and available data from
the AXIS trial, we recommend clinicians, in collaboration
with their patients and other practitioners, establish a strategy
to monitor BP throughout the course of axitinib therapy and
actively manage treatment-induced hypertension.
Prior to axitinib treatment, the clinician should assess the
patient’s BP status, antihypertensive medication use, and car-
diovascular risk factors (Fig. 1). Using past and present BP
measurements, patients may be classified as normotensive,
uncontrolled hypertensive, medication-controlled hyperten-
sive, or sub-optimally medication-controlled hypertensive.
Patients with uncontrolled hypertension may be treated with
short-acting antihypertensive agents for rapid titration and,
once stable, switched to long-acting agents before initiating
axitinib. In those with sub-optimally controlled hypertension,
the dose of current medication may be increased or new
medication(s) added. Pretreatment evaluation of risk factors
for cardiovascular disease, e.g., cardiac conditions, peripheral
vascular disease, renal disease, or diabetes mellitus, is essen-
tial since patients with one or more risk factors may require
closer monitoring during axitinib therapy. Likewise, other
preexisting conditions that may be associated with BP in-
creases, e.g., arterial thromboembolism, diabetes, or cardiac
conditions, should be aggressively managed. The clinician
should be aware if the patient is receiving hypertension-
inducing agents, e.g., steroids or hormones, which may com-
plicate management if axitinib-induced hypertension
develops.
Pretreatment patient education about the importance of BP
assessments, including home monitoring, and the likelihood
of developing hypertension during therapy is critical for
empowering the patient and improving compliance. The cli-
nician should assist in calibrating the home BP-monitoring
device, train the patient in its proper use (additional details
below), and discuss recording and reporting of BP
measurements.
During axitinib therapy, BP should be monitored regularly
in-clinic and at home (Fig. 1). In-clinic and home BP should
be measured with the patient in a seated position and after
resting for 5 min. In-clinic measurements should be recorded
as the mean of at least two measurements taken 3 min apart,
and clinicians should evaluate for white-coat hypertension
[31]. In the AXIS trial [2], in-clinic BP measurements were
performed at baseline, week 2, week 4, and every 4 weeks
thereafter. Clinical trial protocols from the National Cancer
Institute recommend in-clinic BP monitoring every week
during the first cycle of therapy with a VEGF pathway inhib-
itor (for 4 weeks with axitinib) and then every 2–3 weeks
during treatment [32]. For home BP monitoring, patients
shouldmeasure BP prior to axitinib dosing and avoid exercise,
Table 6 Trends in blood pressure measurements over the course of axitinib treatment
No. Minimum 10th percentile Median 90th percentile Maximum
sBP (mmHg)
Baseline 359 85 109.0 125.0 140.0 176
Maximum on treatment 352 95 127.5 143.0 162.0 195
Last on treatment 352 81 108.0 127.5 145.0 175
At follow-upa 118 77 100.0 120.5 140.0 155
dBP (mmHg)
Baseline 359 47 64.5 77.0 87.5 100
Maximum on treatment 352 63 80.0 90.0 103.0 123
Last on treatment 352 55 68.5 80.0 92.0 108
At follow-upa 118 40 60.0 75.5 90.0 101
ΔdBP (mmHg)
Maximum on treatment 352 −18 2.5 14.0 27.0 43
Last on treatment 352 −34 −10.0 4.0 17.5 40
At follow-upa 118 −40 −13.5 1.3 15.0 30
sBP systolic blood pressure, dBP diastolic blood pressure, ΔdBP change in diastolic blood pressure from baseline
a Nearest blood pressure measurement after last day of treatment
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caffeine, and tobacco for at least 30 min prior. Initially, pa-
tients should measure BP twice daily, per AXIS guidelines
[2]; however, home BP monitoring may be relaxed to once
daily after 8 weeks of treatment if BP is controlled and the
axitinib dose has not been modified. All home BP readings
should be recorded in a diary and brought to clinic visits.
Frequency of in-clinic and homemonitoringmay be increased
if BP elevations are observed or if the axitinib dose is
modified.
If hypertension develops during therapy, the axitinib dose
should be reduced or interrupted per AXIS trial recommenda-
tions (Table 1, Fig. 1) and axitinib prescribing information
[23]. Additionally, the dose of current antihypertensive thera-
py may be increased and/or additional antihypertensive med-
ications introduced. Potential drug–drug interactions between
axitinib and antihypertensive medications should be consid-
ered before administration in combination. In vitro studies
have shown that axitinib is primarily metabolized by cyto-
chrome P450 (CYP) 3A4/5 and, to a lesser extent, by
CYP1A2, CYP2C19, and ur id ine d iphospha te -
glucuronosyltransferase 1A1 [23], and therefore unlikely to
have drug–drug interactions with commonly used antihyper-
tensive agents belonging to the class of angiotensin-
converting enzyme inhibitors, including angiotensin II recep-
tor blockers (enalapril, captopril, losartan, vasartan), beta-
blockers (atenolol, metoprolol, labetalol), or diuretics
(hydrochlorothiazide). Within the class of calcium channel
blockers, moderate CYP3A4/5 inhibitors (e.g., verapamil,
diltiazem) were not recommended during the AXIS trial.
Other calcium channel blockers (e.g., amlodipine, bepridil,
felodipine) were less likely to raise axitinib plasma levels
and were allowed during the study. The choice and dosage
of antihypertensive medication should be considered in the
context of the patient’s general medical condition and health
status, in accordance with current standard of care and local
guidelines. Exercise and dietary control, if possible, should be
included in recommendations for managing hypertension.
Clinicians must monitor for hypotension in patients receiving
antihypertensive medications who have their axitinib dose
interrupted [23]. Patients who were previously normotensive
may be more likely to experience rapid BP decreases than
those with prior hypertension (M. Baum, personal communi-
cation) and may require more rigorous monitoring for a few
days after axitinib interruption.
Inhibitors of the VEGF pathway are rarely curative and as a
result, patients may need to be treated with these agents for
extended duration to control their disease. With potential for
RCC to become a chronic disease, management of therapy-
induced BP changes is critical, and the clinician’s goal should
be controlling hypertension throughout treatment of the pri-
mary disease. Proper BP monitoring and management would
be expected to reduce hypertension-related sequelae and may
allow patients to remain on treatment for longer periods [33].
The analyses presented here, and resulting recommendations,
are limited by retrospective analyses and the lack of data for
patient compliance. Observational studies in much larger pop-
ulations of patients with RCC treated with axitinib will be
needed to evaluate hypertension and related sequelae in the
real-world clinical experience.
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